Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program

Table 5 Detailed outcome statistics for opiate free success for selected treatment variables

	Median	Mean	Std. Dev.	% Completed	% Censored	Total N
No. Detox's
1	15.29	23.09	24.64	38.74	61.26	222
2	55.00	53.82	30.07	35.38	64.62	65
3	55.00	61.43	30.00	40.00	60.00	45
4	76.86	78.56	35.66	30.77	69.23	13
5	66.86	78.19	34.35	18.18	81.82	11
6	95.29	95.66	21.45	25.00	75.00	8
7	126.64	126.64	1.92	50.00	50.00	2
Total	25.00	39.04	34.45			366
No. Implants
0	27.29	40.22	35.73	46.72	53.28	274
Single	16.29	28.32	27.57	18.18	81.82	77
Multiple	57.71	56.07	32.49	8.00	92.00	25
Total	25.00	38.84	34.57			376
Type of Treatment
Historicals	56.86	48.83	36.94	55.28	44.72	161
Tablets	21.57	27.96	30.06	34.51	65.49	113
USA	17.14	30.59	28.68	16.67	83.33	78
Perth	51.36	49.84	34.56	12.50	87.50	24
Total	25.00	38.84	34.57			376
Urinary Naltrexone
Absent	36.00	43.48	36.33	47.06	52.94	85
UDS +	30.14	43.75	35.95	27.54	72.46	69
UDS ++-++++	24.00	37.96	32.76	27.93	72.07	111
Total	27.29	41.24	34.75			265

Note on Table interpretation. The first three columns of this table list the days of opiate free success. "Completed" observations refers to patients whose clinical course has been determined be there time of follow-up. Censored observations refer to those patients still in treatment at the time of follow-up, and whose final outcome in treatment therefore remains to be determined at a future time point.

ISSN: 1747-597X